Imbruvica

(Ibrutinib)

Imbruvica

Drug updated on 11/13/2023

Dosage FormCapsule (oral; 70 mg,140 mg); Tablet (oral; 140 mg, 280 mg, 420 mg, 560 mg)
Drug ClassKinase inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of adult patients with mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy.
  • For the treatment of adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL).
  • For the treatment of adult patients with lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion.
  • For the treatment of adult patients with Waldenström’s macroglobulinemia (WM).
  • For the treatment of adult patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.
  • For the treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.

Product Monograph / Prescribing Information

Document TitleYearSource
Imbruvica (ibrutinib) Prescribing Information.2022Pharmacyclics LLC, Sunnyvale CA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Efficacy and safety of front-line treatment regimens for Waldenstrom macroglobulinaemia: a systematic review and meta-analysis. 2023Blood Cancer Journal
Prognostic models predicting overall survival of chronic lymphocytic leukemia (CLL) patients treated with ibrutinib-based therapies: a systematic review and meta-analysis. 2023Leukemia & Lymphoma
Risk of bleeding associated with BTK inhibitor monotherapy: a systematic review and meta-analysis of randomized controlled trials.2022Expert Review Clinical Pharmacology
Ibrutinib-associated dermatologic toxicities: a systematic review and meta-analysis.2022Critical Reviews in Oncology/Hematology
Ibrutinib in refractory or relapsing primary central nervous system lymphoma: a systematic review.2022Neurology International
Systematic Literature Review of Real-World Effectiveness Results Data for First-Line Ibrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. 2022Drugs - Real World Outcomes
Targeted therapies in CLL/SLL and the cumulative incidence of infection: A systematic review and meta-analysis. 2022Frontiers in Pharmacology
Efficacy and safety of ibrutinib in mantle cell lymphoma: A systematic review and meta-analysis. 2022Daru
Risk of bleeding complications and atrial fibrillation associated with ibrutinib treatment: a systematic review and meta-analysis. 2021Critical Reviews in Oncology/Hematology
Efficacy and Safety of Ibrutinib in Central Nervous System Lymphoma: A PRISMA-Compliant Single-Arm Meta-Analysis. 2021Frontiers in Oncology
Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice. 2021Frontiers in Oncology
Risk of bleeding associated with ibrutinib in patients with b-cell malignancies: a systematic review and meta-analysis of randomized controlled trials.2020Frontiers in Pharmacology
Risk of infection associated with Ibrutinib in patients with B-Cell malignancies: a systematic review and meta-analysis of randomized controlled trials. 2020Clinical Lymphoma Myeloma and Leukemia
Risk of infection associated with ibrutinib in patients with B-Cell malignancies: a systematic review and meta-analysis of randomized controlled trials. 2020Clinical Lymphoma Myeloma and Leukemia
Risk of bleeding associated with ibrutinib in patients with bB-cell malignancies: a systematic review and meta-analysis of randomized controlled trials. 2020Frontiers in Pharmacology
Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis. 2020European Journal of Haematology
Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: A single-arm meta-analysis. 2020Critical Review in Oncology/Hematology
Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis.2019PLoS One
Treatment outcomes of novel targeted agents in relapse/refractory chronic lymphocytic leukemia: a systematic review and network meta-analysis.2019Journal of Clinical Medicine
Assessment report : Imbruvica.2019EMA
Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia: A systematic review and meta-analysis of randomized trials. 2019Medicine
Ibrutinib for treating relapsed or refractory mantle cell lymphoma.2018NICE
Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies. 2018European Journal of Haematology
Front-line treatment of patients with chronic lymphocytic leukemia: a systematic review and network meta-analysis. 2018Journal of Comparative Effectiveness Research

Clinical Practice Guidelines